Creative Planning’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.7M | Buy |
8,505
+1,360
| +19% | +$269K | ﹤0.01% | 2035 |
|
|
2025
Q4 | $1.35M | Buy |
7,145
+1,033
| +17% | +$198K | ﹤0.01% | 2046 |
|
|
2025
Q3 | $1.08M | Buy |
6,112
+1,363
| +29% | +$203K | ﹤0.01% | 2041 |
|
|
2025
Q2 | $540K | Buy |
4,749
+503
| +12% | +$53.8K | ﹤0.01% | 2409 |
|
|
2025
Q1 | $446K | Buy |
4,246
+1,012
| +31% | +$114K | ﹤0.01% | 2382 |
|
|
2024
Q4 | $347K | Buy |
3,234
+338
| +12% | +$38.2K | ﹤0.01% | 2543 |
|
|
2024
Q3 | $290K | Buy |
2,896
+111
| +4% | +$11.2K | ﹤0.01% | 2544 |
|
|
2024
Q2 | $235K | Buy |
+2,785
| New | +$222K | ﹤0.01% | 2557 |
|
|
2020
Q1 | – | Sell |
-15,541
| Closed | -$1.01M | – | 1999 |
|
|
2019
Q4 | $1.01M | Sell |
15,541
-18
| -0.1% | -$1.2K | ﹤0.01% | 784 |
|
|
2019
Q3 | $966K | Sell |
15,559
-697
| -4% | -$43.8K | ﹤0.01% | 776 |
|
|
2019
Q2 | $1.16M | Sell |
16,256
-55
| -0.3% | -$4.05K | ﹤0.01% | 706 |
|
|
2019
Q1 | $1.28M | Buy |
16,311
+1,020
| +7% | +$77.3K | ﹤0.01% | 628 |
|
|
2018
Q4 | $1.29M | Sell |
15,291
-2,978
| -16% | -$317K | 0.01% | 564 |
|
|
2018
Q3 | $3.13M | Buy |
18,269
+1,211
| +7% | +$183K | 0.01% | 375 |
|
|
2018
Q2 | $2.2M | Buy |
17,058
+2,015
| +13% | +$225K | 0.01% | 441 |
|
|
2018
Q1 | $1.55M | Sell |
15,043
-158
| -1% | -$15.6K | 0.01% | 534 |
|
|
2017
Q4 | $1.3M | Sell |
15,201
-310
| -2% | -$26.9K | 0.01% | 594 |
|
|
2017
Q3 | $1.32M | Buy |
15,511
+483
| +3% | +$38.2K | 0.01% | 595 |
|
|
2017
Q2 | $1.14M | Sell |
15,028
-306
| -2% | -$21.4K | 0.01% | 626 |
|
|
2017
Q1 | $1.01M | Buy |
15,334
+83
| +0.5% | +$5.46K | 0.01% | 667 |
|
|
2016
Q4 | $967K | Buy |
15,251
+19
| +0.1% | +$1.2K | 0.01% | 636 |
|
|
2016
Q3 | $970K | Sell |
15,232
-1,117
| -7% | -$82K | 0.01% | 604 |
|
|
2016
Q2 | $1.22M | Buy |
16,349
+335
| +2% | +$24.9K | 0.01% | 460 |
|
|
2016
Q1 | $1.07M | Buy |
16,014
+1,273
| +9% | +$77.4K | 0.01% | 481 |
|
|
2015
Q4 | $997K | Sell |
14,741
-80
| -0.5% | -$4.94K | 0.01% | 510 |
|
|
2015
Q3 | $792K | Buy |
+14,821
| New | +$899K | 0.01% | 556 |
|
|
2015
Q2 | – | Sell |
-14,523
| Closed | -$699K | – | 2154 |
|
|
2015
Q1 | $699K | Buy |
14,523
+1,959
| +16% | +$75.1K | 0.01% | 599 |
|
|
2014
Q4 | $417K | Buy |
12,564
+378
| +3% | +$12.3K | ﹤0.01% | 764 |
|
|
2014
Q3 | $357K | Buy |
12,186
+801
| +7% | +$26.6K | ﹤0.01% | 788 |
|
|
2014
Q2 | $442K | Sell |
11,385
-96
| -0.8% | -$3.9K | 0.01% | 689 |
|
|
2014
Q1 | $482K | Buy |
11,481
+11,082
| +2,777% | +$462K | 0.01% | 633 |
|
|
2013
Q4 | $13K | Buy |
399
+320
| +405% | +$10.4K | ﹤0.01% | 2423 |
|
|
2013
Q3 | $2K | Sell |
79
-320
| -80% | -$9K | ﹤0.01% | 2986 |
|
|
2013
Q2 | $9K | Buy |
+399
| New | +$7.18K | ﹤0.01% | 2323 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Creative Planning's LGND Position: Q1 2026 in Review
Creative Planning increased its Ligand Pharmaceuticals (LGND) stake by 19% in Q1 2026, buying an estimated $269K and bringing the position to 8,505 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2035.
Creative Planning first reported a position in LGND in Q2 2013 and has held it in 34 quarters since. The position peaked at $3.13M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Creative Planning held 8,505 shares of Ligand Pharmaceuticals worth $1.7M as of Q1 2026.
- Creative Planning bought 1,360 Ligand Pharmaceuticals shares in Q1 2026, an estimated $269K.
- Ligand Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2035 holding.
- Creative Planning first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
- Creative Planning's Ligand Pharmaceuticals position peaked at $3.13M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.